Trials / Completed

CompletedNCT00122304

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 85 (planned)

Sponsor: Alexion Pharmaceuticals, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH

Conditions

Hemoglobinuria, Paroxysmal

Interventions

Type	Name	Description
DRUG	eculizumab

Timeline

Start date: 2004-12-01
Completion: 2006-11-01
First posted: 2005-07-22
Last updated: 2007-02-21

Locations

48 sites across 13 countries: United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00122304. Inclusion in this directory is not an endorsement.